Identification of Novel Protein Biomarkers in the Era of Precision Medicine Oncology

Presented By: Hilal Arnouk, MD, PhD
Speaker Biography: Hilal Arnouk, MD, PhD is an Associate Professor at the Department of Pathology at Midwestern University. Dr. Arnouk has received his education and post-doctorate training at Roswell Park Cancer Institute, the State University of New York at Buffalo, the Medical College of Georgia and the University of Alabama at Birmingham. He has directed research studies in academia and biotech industry settings. His major areas of expertise include Cancer Immunotherapy, Biomarker Discovery and Precision Medicine. Additionally, Dr. Arnouk tremendously enjoys being an educator for professional students in the medical and biomedical sciences.
Webinar: Identification of Novel Protein Biomarkers in the Era of Precision Medicine Oncology
Webinar Abstract: Cancer is a leading cause of morbidity and mortality in developed countries including the United States. Early detection of various cancers, before they spread and become incurable, has been the best weapon in the war on cancer that began with the signing of the National Cancer Act in 1971. The premise of Precision Medicine is the ability to customize personalized medical care to individual patients through the incorporation of molecular profiles and clinical characteristics in treatment determination utilizing molecular diagnostics, and targeted therapies.
Proteins uniquely produced by tumors and their surrounding microenvironment constitute valuable biomarkers that aid in diagnosis of initial tumors, screening the population, monitoring of tumor progression, metastases, response to treatment and relapse (e.g., the prostate-specific antigen, PSA, is routinely used for screening and monitoring of prostate cancer). Moreover, some biomarkers can stratify patients into sub-groups that differ in their prognosis and response to different treatment options, which allows designing individual treatment plans. For instance, the human epidermal growth factor receptor 2 (Her2-neu) is overexpressed in about 20% of breast cancer patients and can be targeted by a monoclonal antibody called Herceptin in these patients, which enhances the overall survival when combined with chemotherapy.
Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots www.labroots.c...
2. Watch the webinar on UA-cam or on the LabRoots Website www.labroots.c...
3. Click Here to get your PACE credits (Expiration date - February 23, 2024): www.labroots.c...
LabRoots on Social:
Facebook: / labrootsinc
Twitter: / labroots
LinkedIn: / labroots
Instagram: / labrootsinc
Pinterest: / labroots
SnapChat: labroots_inc